Skip to main content
    G

    Genmab AS (GMAB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $51.96
    +0.39 (+0.76%)

    Market Cap: $31.80B

    Last updated: Nov 17, 2026 at 4:33 PM ET

    Genmab AS (GMAB) Stock Chart

    Updated Nov 17, 2026. Prices from end-of-day market data; valuation figures from company filings.

    Genmab AS (GMAB) has a latest price of $51.96 on Nov 17, 2026, 13.4% below its 52-week high of $59.97. Its price rose 71.7% over the past 12 months. The month-end price rose 242.2% over the 10 years through Oct 2026, a compound annual rate of 13.1%.

    Price Chart

    From Oct 2016 to Oct 2026, its highest month-end close was $57.06 in Oct 2026 and its lowest $13.67 in Oct 2018, adjusted for splits.

    Month-end closes, adjusted for splits. Dividends are not included.

    Chart GMAB with Advanced Charting

    Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for GMAB.

    Free with a GNG account. No credit card.

    Price Performance

    Over the past 3 months the price rose 52.3%, and over 6 months it rose 102.3%. The month-end price rose 100.9% over the 3 years through Oct 2026, a compound annual rate of 26.2%.

    PeriodChange
    1 month+35.0%
    3 months+52.3%
    6 months+102.3%
    12 months+71.7%
    12 months, with dividends+71.7%
    Price change over each period. Dividends are not included unless the row says so.
    PeriodChangePer year
    3 years+100.9%+26.2%
    5 years+27.8%+5.0%
    10 years+242.2%+13.1%
    From month-end closes through Oct 2026. Per year is the compound annual rate.

    Price by Year

    Its best calendar year was 2020, when the price rose 82.1%, and its weakest was 2024, when it fell 34.5%.

    YearCloseChange
    2026 through Oct 2026$57.06+85.3%
    2025$30.80+47.6%
    2024$20.87-34.5%
    2023$31.84-24.9%
    2022$42.38+7.1%
    2021$39.56-2.7%
    2020$40.66+82.1%
    2019$22.33+35.5%
    2018$16.48-0.6%
    2017$16.580.0%
    Each year ends at its December month-end close, adjusted for splits.

    Trading Range

    The price is 24.1% above its 50-day average of $41.88 and 63.8% above its 200-day average of $31.73.

    MeasureValuePrice vs
    Latest price (Nov 17, 2026)$51.96
    52-week high$59.97-13.4%
    52-week low$23.62+120.0%
    50-day average$41.88+24.1%
    200-day average$31.73+63.8%
    Moving averages of daily closes. The last column compares the price with each level.

    Price Risk

    Over 3 years, its largest fall from a peak was 45.1%.

    MeasureValue
    1-year beta0.89
    Largest fall, 1 year-32.5%
    Largest fall, 3 years-45.1%
    Beta against the S&P 500 over one year. A fall is measured from a peak to the low after it.

    Advanced Charting Features

    Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.

    • Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
    • Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
    • Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
    • Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.

    Frequently Asked Questions About GMAB

    What is GMAB's 1-year price change?

    Genmab AS's price rose 71.7% over the past 12 months. With dividends included, the 12-month total return was 71.7%.

    What is GMAB's 5-year price change?

    Genmab AS's month-end price rose 27.8% over the 5 years through Oct 2026, a compound annual rate of 5.0%. These figures leave out dividends.

    What is GMAB's 52-week high and low?

    Genmab AS's 52-week high is $59.97 and its 52-week low is $23.62. Its latest price of $51.96 on Nov 17, 2026 is 13.4% below the high.

    What is GMAB's beta?

    Genmab AS's 1-year beta against the S&P 500 is 0.89, so its price has moved about in line with the market over the past year. Its largest fall from a peak over the past year was 32.5%.

    Is the GMAB chart free?

    Yes. Advanced Charting for GMAB is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.